362 related articles for article (PubMed ID: 38021410)
1. Antifungal resistance, combinations and pipeline: oh my!
Stover KR; Hawkins BK; Keck JM; Barber KE; Cretella DA
Drugs Context; 2023; 12():. PubMed ID: 38021410
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Hoenigl M; Sprute R; Egger M; Arastehfar A; Cornely OA; Krause R; Lass-Flörl C; Prattes J; Spec A; Thompson GR; Wiederhold N; Jenks JD
Drugs; 2021 Oct; 81(15):1703-1729. PubMed ID: 34626339
[TBL] [Abstract][Full Text] [Related]
4. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
Lamoth F; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
[TBL] [Abstract][Full Text] [Related]
5. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments.
Gintjee TJ; Donnelley MA; Thompson GR
J Fungi (Basel); 2020 Feb; 6(1):. PubMed ID: 32106450
[TBL] [Abstract][Full Text] [Related]
6. Antifungal Resistance and the Role of New Therapeutic Agents.
Logan A; Wolfe A; Williamson JC
Curr Infect Dis Rep; 2022; 24(9):105-116. PubMed ID: 35812838
[TBL] [Abstract][Full Text] [Related]
7. The antifungal pipeline for invasive fungal diseases: what does the future hold?
Neoh CF; Jeong W; Kong DC; Slavin MA
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):577-594. PubMed ID: 37057677
[TBL] [Abstract][Full Text] [Related]
8. How urgent is the need for new antifungals?
Stewart AG; Paterson DL
Expert Opin Pharmacother; 2021 Oct; 22(14):1857-1870. PubMed ID: 34231434
[No Abstract] [Full Text] [Related]
9. Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline.
Khalfe Y; Rosen T
J Drugs Dermatol; 2022 May; 21(5):496-501. PubMed ID: 35533026
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Lamoth F
Infect Drug Resist; 2023; 16():1087-1097. PubMed ID: 36855391
[TBL] [Abstract][Full Text] [Related]
11. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R
Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026
[TBL] [Abstract][Full Text] [Related]
12. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective.
Hsu AJ; Hanisch BR; Fisher BT; Huppler AR
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S68-S79. PubMed ID: 38417087
[TBL] [Abstract][Full Text] [Related]
13. Novel antifungal agents in clinical trials.
Jacobs SE; Zagaliotis P; Walsh TJ
F1000Res; 2021; 10():507. PubMed ID: 35136573
[TBL] [Abstract][Full Text] [Related]
14. Antifungal Combinations against
Fioriti S; Brescini L; Pallotta F; Canovari B; Morroni G; Barchiesi F
J Fungi (Basel); 2022 Oct; 8(10):. PubMed ID: 36294642
[TBL] [Abstract][Full Text] [Related]
15. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
16. Emerging Diagnostics and Therapeutics for Invasive Fungal Infections.
Friedman DZP; Schwartz IS
Infect Dis Clin North Am; 2023 Sep; 37(3):593-616. PubMed ID: 37532392
[TBL] [Abstract][Full Text] [Related]
17. Recent Antifungal Pipeline Developments against
Treviño-Rangel RJ; González GM; Montoya AM; Rojas OC; Elizondo-Zertuche M; Álvarez-Villalobos NA
J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354911
[TBL] [Abstract][Full Text] [Related]
18. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.
Gamaletsou MN; Walsh TJ; Sipsas NV
Turk J Haematol; 2018 Mar; 35(1):1-11. PubMed ID: 29391334
[TBL] [Abstract][Full Text] [Related]
19. Investigational Agents for the Treatment of Resistant Yeasts and Molds.
Seiler GT; Ostrosky-Zeichner L
Curr Fungal Infect Rep; 2021; 15(3):104-115. PubMed ID: 34075318
[TBL] [Abstract][Full Text] [Related]
20. A Mini-Review of In Vitro Data for
Espinel-Ingroff A; Wiederhold NP
J Fungi (Basel); 2024 May; 10(5):. PubMed ID: 38786717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
